Study of LW231 in Participants With Chronic Hepatitis B

Summary

This is a Phase Ib/II, multicenter, randomized, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of LW231 in participants with chronic hepatitis B virus (HBV) infection. The trial will include multiple-dose regimens of LW231 and assess LW231 in combination with NUCs.

Timeline

Start

2025-10

Primary completion

2027-03

Completion

2027-11

Drugs

Indications